Nonetheless, in the immunosuppressive tumor milieu, fused antigen receptor (CAR) T-cell therapy has limited effectiveness against dense tumors as adenosine is a major factor in the suppression of T-cell responses by activating adenosine 2A receptor (A2aR). This evidence concerns the gene ADORA2A and neoplasm.